STOCK TITAN

Vivani Medical (VANI) Stock News, Aug 2025-Jan 2026

VANI NASDAQ

Vivani Medical, Inc. reports developments from a clinical-stage biopharmaceutical business focused on miniature, ultra long-acting subdermal drug implant candidates using its proprietary NanoPortal™ technology. News commonly centers on financial results, business updates, manufacturing and clinical-development spending, and progress for semaglutide-based implant candidates such as NPM-139 for chronic weight management and NPM-133 for type 2 diabetes.

The company’s updates also cover Cortigent, its wholly owned subsidiary developing brain implant devices based on precision neurostimulation technology. Cortigent disclosures include the Orion® Visual Cortical Prosthesis System, a cortical stimulation system under development to provide visual perception for blind persons, as well as equity financings, registered direct offerings, private placements, shareholder matters and governance updates.

Rhea-AI Summary

Vivani (NASDAQ: VANI) subsidiary Cortigent will present an award-winning poster on Jan 23, 2026 at the North American Neuromodulation Society annual meeting describing the investigational Orion Visual Cortical Prosthesis System. The company says Orion completed a six-year Early Feasibility Study and is designed to elicit visual phosphenes via a 60-electrode cortical surface array paired to an implantable pulse generator with 60 outputs in a package about the size of three stacked dimes and a wireless wearable for real-time processing.

The poster highlights miniature, high-channel-count stimulation and real-time parameter control; it notes the electrode design derives from retinal implant experience with Argus II, which remained functional in retinal tissue for >17 years and was the only FDA-approved artificial vision device.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
none
-
Rhea-AI Summary

Vivani Medical (Nasdaq: VANI) reported third quarter 2025 results and a business update on Nov 13, 2025. The company completed LIBERATE-1, its first human test of the NanoPortal implant, and reported preclinical NPM-139 data showing 20% weight loss sustained for over 7 months. Vivani plans to initiate a Phase 1 semaglutide implant study in the first half of 2026 and is preparing a Phase 2 dose-ranging study pending Phase 1 results and regulatory feedback.

Financings in 3Q and October generated approximately $25.7 million in cash and commitments to support NPM-139 development and, as of Sept 30, 2025, Vivani held $4.0 million in cash. The company expects to complete the spin-off of Cortigent after the SEC resumes operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.44%
Tags
-
Rhea-AI Summary

Vivani Medical (Nasdaq: VANI) closed a registered direct offering of 6,000,000 common shares and a concurrent private placement of 3,703,703 common shares on Oct 28, 2025 at $1.62 per share, generating approximately $15.7 million gross before fees and expenses.

The private placement purchaser was Gregg Williams, Chairman of Vivani’s board. The offerings were priced at-the-market under Nasdaq rules and used a Form S-3 shelf registration declared effective May 3, 2024. Net proceeds are intended to fund research and clinical development, plus working capital and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
Rhea-AI Summary

Vivani Medical (Nasdaq: VANI) priced a best-efforts registered direct offering of 6,000,000 common shares and a concurrent private placement of 3,703,703 common shares to Gregg Williams at $1.62 per share.

The combined gross proceeds are expected to be approximately $15.7 million before fees and expenses; closing is expected on or about October 28, 2025, subject to customary conditions. ThinkEquity is sole placement agent. Proceeds are intended to fund ongoing research and clinical development, plus working capital and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
-
Rhea-AI Summary

Vivani Medical (NASDAQ: VANI) announced that CEO Adam Mendelsohn, Ph.D. will present at the ThinkEquity Conference on October 30, 2025 in New York.

Presentation is scheduled for 1:30 p.m. Eastern Time at the Lotus Suite East, Mandarin Oriental Hotel, 80 Columbus Circle. A webcast will be available on the company Investors page and via the provided Summitcast link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.60%
Tags
conferences
-
Rhea-AI Summary

Vivani Medical (NASDAQ: VANI) announced on Oct 3, 2025 that it has temporarily withdrawn the previously announced record date for the planned spin-off of its wholly owned subsidiary Cortigent, which develops brain implant neuromodulation devices. The withdrawal is due to delays arising from the current shutdown of the U.S. federal government. Vivani expects to reestablish and announce a new record date as soon as possible. The press release notes that ThinkEquity is acting as exclusive financial advisor to Cortigent for the spin-off transaction and provides a link to ThinkEquity for more information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.50%
Tags
none
Rhea-AI Summary

Vivani Medical (NASDAQ: VANI), a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting drug implants, will present at the Emerging Growth Conference 86 on September 25, 2025.

Company President and CEO Adam Mendelsohn, Ph.D. will deliver a 30-minute presentation starting at 1:45 PM Eastern Time, providing a company overview followed by a Q&A session. Investors, analysts, and advisors are invited to participate in this interactive online event, with the opportunity to submit questions in advance to Questions@EmergingGrowth.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.00%
Tags
conferences
-
Rhea-AI Summary

Vivani Medical (NASDAQ: VANI) has announced the record date of October 8, 2025 for the spin-off of its neuromodulation subsidiary, Cortigent. Cortigent will become an independent, publicly-traded company on Nasdaq under the ticker symbol CRGT.

Cortigent specializes in brain implant devices and has achieved significant milestones, including FDA approval for its Orion® artificial vision system for the profoundly blind and completion of a 6-year Early Feasibility Study. The company is also developing a Stroke Recovery System for improving arm and hand motion in stroke patients.

Post spin-off, Vivani will focus on developing miniature, ultra long-acting GLP-1 implants for weight loss and type 2 diabetes treatment. The transaction is expected to complete by late-2025, subject to regulatory approvals and other conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.83%
Tags
none
-
Rhea-AI Summary

Vivani Medical (Nasdaq: VANI) has announced plans to initiate clinical trials for NPM-139, their semaglutide implant for chronic weight management. The company plans to begin a Phase 1 study in the first half of 2026, pending regulatory clearance, followed by a Phase 2 study.

The NPM-139 implant, utilizing NanoPortal™ technology, aims to provide Wegovy®-level efficacy with just once or twice-yearly administration. The Phase 1 study will evaluate safety, tolerability, and pharmacokinetics in GLP-1 naïve obese or overweight subjects, with low-dose Wegovy as control. The subsequent Phase 2 study will be a randomized, placebo-controlled, dose-ranging investigation over 4-6 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.10%
Tags
Rhea-AI Summary

Vivani Medical (NASDAQ: VANI), a clinical-stage biopharmaceutical company, announced that CEO Adam Mendelsohn will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, in New York.

The presentation will showcase Vivani's portfolio of miniature, ultra long-acting drug implants powered by their proprietary NanoPortal™ technology. The company's focus is on addressing medication adherence in chronic disease management, with particular emphasis on NPM-139, a novel semaglutide implant scheduled for clinical development in 2026, pending regulatory approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
conferences

FAQ

What is the current stock price of Vivani Medical (VANI)?

Vivani Medical (VANI) last closed at $1.05.

What is the market cap of Vivani Medical (VANI)?

The market cap of Vivani Medical (VANI) is approximately $94.7M.